Blood cell therapy最新文献

{"title":"Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.","authors":"Masahiro Yoshida, Yoshinori Matsuoka, Satoshi Mitsuyuki, Noboru Yonetani, Junichi Kawai, Tadakazu Kondo, Takayuki Ishikawa","doi":"10.31547/bct-2023-021","DOIUrl":"10.31547/bct-2023-021","url":null,"abstract":"<p><strong>Introduction: </strong>Cytokine release syndrome (CRS) is a life-threatening side effect of chimeric antigen receptor T (CAR-T) cell therapy. This study investigated whether serum inorganic phosphate (IP) and magnesium (Mg) levels are predictive markers of CRS development.</p><p><strong>Methods: </strong>This single-center retrospective cohort study enrolled 16 consecutive patients with diffuse large B-cell lymphoma who had received CAR-T cell therapy. Logistic regression models with generalized estimating equations were used to evaluate whether changes in IP and Mg levels from their baseline values were associated with the development of CRS within 48 hours.</p><p><strong>Results: </strong>Decreased IP and Mg levels from baseline (per 10% change) were associated with an increased CRS incidence (adjusted odds ratio 2.18 [95% confidence interval (CI), 1.31-3.62], 3.18 [95% CI, 1.57-6.44], respectively).</p><p><strong>Conclusions: </strong>Changes in IP and Mg concentrations within 48 hours may be useful predictive markers of CRS onset.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 4","pages":"129-134"},"PeriodicalIF":0.0,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Accuracy of Professional Continuous Glucose Monitoring in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Shigeki Nagao,&nbsp;Kimikazu Yakushijin,&nbsp;Ako Higashime,&nbsp;Koji Kawaguchi,&nbsp;Marika Watanabe,&nbsp;Rina Sakai,&nbsp;Hiroya Ichikawa,&nbsp;Yu Mizutani,&nbsp;Hideaki Goto,&nbsp;Seiji Kakiuchi,&nbsp;Keiji Kurata,&nbsp;Akihito Kitao,&nbsp;Yoshiharu Miyata,&nbsp;Yoshinori Imamura,&nbsp;Yushi Hirota,&nbsp;Michiko Takahashi,&nbsp;Shinichiro Kawamoto,&nbsp;Katsuya Yamamoto,&nbsp;Hiroshi Matsuoka,&nbsp;Hironobu Minami","doi":"10.31547/bct-2022-024","DOIUrl":"https://doi.org/10.31547/bct-2022-024","url":null,"abstract":"<p><p>Hyperglycemia in the early days following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-known risk factor for acute graft-versus-host disease (GVHD) and non-relapse mortality. The FreeStyle Libre Pro, a factory calibrated continuous glucose monitoring (CGM) device, has been used for the retrospective analysis of glucose testing in patients with diabetes. We assessed the safety and accuracy of the device in patients undergoing allo-HSCT. We recruited eight patients who underwent allo-HSCT between August 2017 and March 2020. They wore the FreeStyle Libre Pro on the day before or on the day of transplantation until 28 days after transplantation. Adverse events, especially bleeding and infection, were monitored to assess safety, and blood glucose levels were measured and compared with the device values. None of the eight participants experienced bleeding that was difficult to stop from the sensor site or local infection that required antimicrobial administration. The device value was well correlated with blood glucose (correlation coefficient r=0.795, <i>P</i><0.01); however, the overall mean absolute relative difference was 32.1%±16.0%. Our study demonstrated the safety of FreeStyle Libre Pro in allo-HSCT patients. However, the sensor results tended to be lower than the blood glucose levels.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 2","pages":"54-60"},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/af/2432-7026-6-2-0054.PMC10279490.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation.","authors":"Takanori Teshima,&nbsp;Jaap Jan Boelens,&nbsp;Ken-Ichi Matsuoka","doi":"10.31547/bct-2022-023","DOIUrl":"https://doi.org/10.31547/bct-2022-023","url":null,"abstract":"<p><p>Effective control of the graft-versus-host disease (GVHD) and immune reconstitution are crucial in improving the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) as well as the quality of life of the transplant survivors. Recent basic and clinical studies have deepened our understanding of the mechanisms of the immunological sequelae of HSCT, GVHD, and compromised immune systems. Based on the findings, various novel approaches have also been developed and tested clinically. However, further studies are necessary to develop therapeutic strategies with significant clinical benefits.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 2","pages":"42-48"},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/66/2432-7026-6-2-0042.PMC10279491.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old.","authors":"Takahiro Shima,&nbsp;Ken Takigawa,&nbsp;Sae Utsumi,&nbsp;Teruhiko Yoshino,&nbsp;Megumi Naganuma,&nbsp;Mariko Minami,&nbsp;Masayasu Hayashi,&nbsp;Yayoi Matsuo,&nbsp;Takuro Kuriyama,&nbsp;Tetsuya Eto","doi":"10.31547/bct-2022-018","DOIUrl":"https://doi.org/10.31547/bct-2022-018","url":null,"abstract":"<p><p>Hematologic diseases frequently affect people >60 years old, and allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment for these patients. Although several multicenter studies proposed the risk assessment of allo-SCT for the elderly, they receive different treatments and management at each facility. Therefore, accumulating data from institutions that exhibit relatively the same treatment policy and patient care is important. This retrospective study aimed to clarify the prognostic factors of allo-SCT for the elderly in our institution. Of the 104 patients, 51.0% were 60-64 years old, and 49.0% were ≥65 years old. The 3-year overall survival (OS) was 40.9% and 35.7% for patients 60-64 and ≥65 years old, respectively, which is not significant. While the disease status prior to allo-SCT demonstrated strong effects on the 3-year OS for patients that are 60-64 years old (in remission, 76.9%; non-remission, 15.7%, <i>p</i><0.001), this effect was smaller for patients ≥65 years old (in remission, 43.1%; non-remission, 30.1%, <i>p</i>=0.048). Multivariate analysis revealed that the performance status (PS), not the disease status prior to allo-SCT, was the prognostic risk factor of OS for patients aged ≥65 years. Our data suggest that PS is a useful predictor of better OS following allo-SCT, especially for patients ≥65 years old.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 2","pages":"30-41"},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/5c/2432-7026-6-2-0030.PMC10279488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of severe oral mucosal GVHD induced by heterologous SARS-CoV-2 vaccination after cord blood transplantation.","authors":"Kazuhiro Sanda,&nbsp;Shigeo Fuji,&nbsp;Hidetoshi Satomi,&nbsp;Masanori Kitamura,&nbsp;Nao Nishimura,&nbsp;Yuma Tada,&nbsp;Yasuhiro Shingai,&nbsp;Sayako Yuda,&nbsp;Takafumi Yokota,&nbsp;Jun Ishikawa","doi":"10.31547/bct-2022-019","DOIUrl":"https://doi.org/10.31547/bct-2022-019","url":null,"abstract":"<p><p>Patients who have undergone hematopoietic cell transplantation (HCT) are at a higher risk of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection than the general population. Therefore, early vaccination is recommended for post-transplant patients. Although exacerbation of chronic graft-versus-host disease (cGVHD) after the initial vaccination has been reported, it is unknown whether severe cGVHD occurs when different RNA vaccines are combined. We treated a patient who developed severe oral mucosal cGVHD after receiving two different RNA vaccines. Visual inspection showed that the patient presented with typical mucocutaneous cGVHD, and cGVHD in this case responded well to low-dose steroids compared to common oral GVHD exacerbations. Histopathological findings revealed T cell, B cell, and conspicuous neutrophil infiltration. Multiple doses of SARS-Cov2 vaccination are required in post-transplant recipients. In conclusion, it is essential to obtain the vaccination history of allo-HSCT recipients with cGVHD exacerbation. Furthermore, reviewing the pathological findings may help treat patients with lower doses of steroids.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 2","pages":"49-53"},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/51/2432-7026-6-2-0049.PMC10279489.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10086114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance.","authors":"Ashwin Nair,&nbsp;Shaweta Kaundal,&nbsp;Kripa Shanker Kasudhan,&nbsp;Madhu Chopra,&nbsp;Charanpreet Singh,&nbsp;Aditya Jandial,&nbsp;Arihant Jain,&nbsp;Gaurav Prakash,&nbsp;Alka Khadwal,&nbsp;Archana Angrup,&nbsp;Amol Patil,&nbsp;Pallab Ray,&nbsp;Pankaj Malhotra,&nbsp;Deepesh P Lad","doi":"10.31547/bct-2022-020","DOIUrl":"https://doi.org/10.31547/bct-2022-020","url":null,"abstract":"<p><strong>Introduction: </strong>The role of fluoroquinolone (FQ) prophylaxis in preventing gram-negative bacilli (GNB) bacteremia, graft-versus-host disease (GVHD), and overall survival (OS) after allogeneic hematopoietic cell transplantation (allo-HCT) is debatable and may differ in settings with low and high prevalences of FQ resistance. In this study, we aimed to answer this question in regions with high FQ resistance.</p><p><strong>Methods: </strong>This single-center retrospective study included all consecutive allo-HCT recipients aged ≥12 years from 2012 to 2021. Allo-HCT recipients until 2016 were administered FQ prophylaxis (levofloxacin). After 2016, the institutional protocol was modified to no antibiotic prophylaxis. Data were retrieved from patient records for disease and transplant characteristics, the incidence of GNB bacteremia, duration of parenteral antibiotics, hospitalization duration, acute GVHD, and OS.</p><p><strong>Results: </strong>A total of 135 allo-HCT recipients (43 in the FQ-prophylaxis cohort and 92 in the no-antibiotic prophylaxis cohort) were analyzed in this study. The two cohorts were matched for age (median, 26 vs. 24.5 years; <i>p</i> = 0.8). The no-antibiotic prophylaxis cohort had a higher proportion of malignant diagnoses (80% vs. 58%, <i>p</i> = 0.01), haploidentical transplants (46% vs. 14%, <i>p</i> = 0.004), and posttransplant cyclophosphamide exposure (46% vs. 14%, <i>p</i> = 0.003) than did the FQ cohort. Despite this, the incidence of GNB bacteremia was not significantly different between the two cohorts (37% vs. 34%, <i>p</i> = 0.6). There were no differences in parenteral antibiotic use or hospitalization duration, as well as the incidence of acute GVHD (53% vs. 53%, <i>p</i> = 0.3). The 1-year OS was similar between the two cohorts (66% vs. 67%, <i>p</i> = 0.6).</p><p><strong>Conclusion: </strong>This study shows that FQ prophylaxis did not affect the incidence of GNB bacteremia, parenteral antibiotic use, hospitalization duration, acute GVHD, and OS post-allo-HCT.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 2","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/38/2432-7026-6-2-0061.PMC10279926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9765685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Transplant Complications.","authors":"Khalid Halahleh,&nbsp;Yasuyuki Arai,&nbsp;Eleni Gavriilaki","doi":"10.31547/bct-2022-021","DOIUrl":"https://doi.org/10.31547/bct-2022-021","url":null,"abstract":"<p><p>Hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with high-risk malignant and nonmalignant conditions. Nevertheless, various post-allogeneic HCT (allo-HCT) complications with diverse chronology, etiology, and pathophysiological background can develop, including general and organ-specific complications, such as graft dysfunction, infectious, and non-infectious etiologies, as well as non-infectious pulmonary complications (NIPCs). Post-transplant complications can also be related to conditioning intensity and drug-specific side effects. However, treatment options for these complications are suboptimal at present. Poor graft function (PGF) is a potentially life-threatening post-allo-HCT complication and is reported in 5-30% of patients. Nevertheless, consensus guidelines to define and treat PGF are not available. Most therapies are symptomatic with variable success rates. NIPCs are diverse and difficult to diagnose. The pathophysiology of NIPCs remains ill-defined, and effective treatment approaches have not been standardized, with mortality exceeding 50% for some conditions, such as idiopathic pneumonia syndrome (IPS). Modification of the conditioning regimen intensity and introduction of novel agents have been used to decrease post-allo-HCT complications, including infections, non-infectious complications, graft-<i>versus</i>-host disease (GvHD), as well as cardiopulmonary, neurological, hepatorenal, and other complications. Transplant-associated thrombotic microangiopathy (TA-TMA) is a lethal post-allo-HCT complication that may be associated with functional and genetic abnormalities in complement activation and related to the use of calcineurin inhibitors, such as cyclosporine and tacrolimus. The introduction of complement inhibitors has transformed TA-TMA from a lethal complication to a treatable syndrome.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 1","pages":"23-29"},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/cb/2432-7026-6-1-0023.PMC10266915.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center.","authors":"Prashant Chhabra,&nbsp;Kripa Shanker Kasudhan,&nbsp;Niranjan Khaire,&nbsp;Shaweta Kaundal,&nbsp;Madhu Chopra,&nbsp;Charanpreet Singh,&nbsp;Aditya Jandial,&nbsp;Arihant Jain,&nbsp;Gaurav Prakash,&nbsp;Alka Khadwal,&nbsp;Pankaj Malhotra,&nbsp;Deepesh P Lad","doi":"10.31547/bct-2022-017","DOIUrl":"https://doi.org/10.31547/bct-2022-017","url":null,"abstract":"<p><p>Assessing acute and chronic graft-versus-host disease (GVHD) is challenging because there are several classification systems. The European Society for Blood and Marrow Transplantation and the Center for International Bone Marrow Transplantation Registry task force recommends using the eGVHD application (App) to score acute GVHD according to the Mount Sinai Acute GvHD International Consortium (MAGIC) criteria and chronic GVHD according to the National Institutes of Health 2014 criteria. We prospectively used the eGVHD App at each follow-up visit in a large-volume bone-marrow transplant center in India from 2017 to 2021. We retrospectively evaluated the discrepancy in scoring GVHD severity by physicians not using the App from the same patient charts. The App user satisfaction and experience were recorded using the technology acceptance model (TAM) and the Post-Study System Usability Questionnaire (PSSUQ). In 100 consecutive allogeneic hematopoietic cell transplantation recipients, there was more discrepancy in scoring the severity of chronic GVHD (38%) than acute GVHD (9%) without using the App. The median TAM and PSSUQ scores were six (IQR:1) and two (IQR:1), respectively, indicating high perceived usefulness and user satisfaction. The eGVHD App is an excellent learning tool for hematology/BMT fellows and helps manage GVHD in high-volume BMT centers.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 1","pages":"18-22"},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/c7/2432-7026-6-1-0018.PMC10266919.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study.","authors":"Dharma Choudhary,&nbsp;Divya Doval,&nbsp;Vipin Khandelwal,&nbsp;Rasika Setia,&nbsp;Anil Handoo","doi":"10.31547/bct-2022-003","DOIUrl":"https://doi.org/10.31547/bct-2022-003","url":null,"abstract":"<p><strong>Introduction: </strong>Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment option for myelofibrosis (MF). Despite the benefits of long-term relapse-free survival, HSCT can be associated with substantial treatment-related morbidity and mortality.</p><p><strong>Methods: </strong>This is an observational retrospective study of 15 consecutive patients with MF who underwent allogeneic HSCT at a tertiary care center in Northern India between June 2012 and January 2020. The pre-transplant Dynamic International Prognostic Scoring System (DIPSS) and hematopoietic cell transplantation-specific co-morbidity index (HCT-CI) scores were used. The primary endpoints were overall survival (OS) and disease-free survival (DFS), and the secondary endpoints were post-transplant complications (acute and chronic graft-versus-host-disease [GvHD], graft failure [GF], and cytomegalovirus reactivation [CMV]).</p><p><strong>Results: </strong>The OS and DFS in our study were 60% with no relapse at a median follow-up of 364 days (range 7-2,815 days). Twenty-seven percent of patients developed acute GvHD and 27% of patients developed chronic (limited) GvHD. The non-relapse mortality (NRM) was 40%, with the main cause of death being sepsis, followed by acute GvHD.</p><p><strong>Conclusion: </strong>MF remains a challenging condition to treat, with a poor prognosis. Our study showed that reduced toxicity conditioning provided good DFS and OS. Thus, it should be offered to patients with high DIPSS scores. Sepsis was the predominant cause of mortality in this cohort.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/63/2432-7026-6-1-0005.PMC10266917.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary veno-occlusive disease after respiratory syncytial virus infection in a post hematopoietic stem cell transplantation patient.","authors":"Tatsuo Watanabe,&nbsp;Kazutoshi Komori,&nbsp;Shoji Saito,&nbsp;Eriko Uchida,&nbsp;Takashi Kurata,&nbsp;Masatomo Kitamura,&nbsp;Hikoro Matsui,&nbsp;Kohta Takei,&nbsp;Yoshifumi Ogiso,&nbsp;Keiko Ohta-Ogo,&nbsp;Yozo Nakazawa,&nbsp;Kazuo Sakashita","doi":"10.31547/bct-2022-005","DOIUrl":"https://doi.org/10.31547/bct-2022-005","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary veno-occlusive disease (PVOD) is a rare but fatal complication of hematopoietic stem cell transplantation (HSCT). Although literature on PVOD post-HSCT is scarce, a recent study has indicated that this condition may be underestimated. Respiratory syncytial virus (RSV) is a common respiratory pathogen that causes common cold in healthy individuals but may lead to severe lower respiratory infection accompanied by respiratory distress in infants and immunocompromised individuals, such as post-HSCT patients. However, little is known about the relationship between PVOD and RSV infections.</p><p><strong>Case report: </strong>A 4-year-old boy was diagnosed with metastatic neuroblastoma and underwent intensive chemotherapy, autologous HSCT, and allogeneic cord blood transplantation (CBT). He experienced PVOD on day 194 following CBT after displaying upper respiratory symptoms and positive RSV antigen test results approximately one month prior. Pathological examination of a lung biopsy specimen revealed lung injury suspected to be associated with viral infection in addition to PVOD-related findings, suggesting that RSV infection might have contributed to the onset of PVOD.</p><p><strong>Conclusions: </strong>The patient's clinical history and histological findings indicated that RSV could have triggered the development of PVOD under potential endothelial damage caused by HSCT and other prior treatments. Common respiratory viral infections, such as RSV infection, may evoke the development of PVOD.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/c6/2432-7026-6-1-0001.PMC10266921.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}